GlassScriptPhysician profile
Krishna Duvvuri
NPI 1073574745
$2,107.28
in general payments reported to CMS, 2019-2025
25 companies · $315 in 2025
The $315 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2022: $195 · 2023: $718 · 2024: $489 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,521.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $282.50 | 2022-2025 | |
| Medtronic, INC. | $196.79 | 2022-2025 | Minimed 780g |
| Dexcom, INC. | $171.59 | 2022-2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $156.66 | 2022-2025 | Wegovy |
| Pfizer INC. | $153.21 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.33 | 2019-2023 | Jardiance |
| Atricure, INC. | $140.52 | 2019 | |
| Amgen INC. | $135.69 | 2022-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $124.99 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $93.29 | 2023-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $82.50 | 2023 | Verquvo, Steglatro |
| Corcept Therapeutics | $63.68 | 2024-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $53.07 | 2023-2025 | Gvoke Hypopen |
| Abbott Laboratories | $52.65 | 2022-2023 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $49.13 | 2023-2024 | Nexletol |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $35.01 | 2023-2024 | Inpefa |
| Lilly USA, LLC | $32.31 | 2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $29.62 | 2023-2024 | Eliquis |
| Impulse Dynamics (USA) INC. | $18.51 | 2023 | Optimizer |
| Agios Pharmaceuticals, INC. | $17.06 | 2025 | Pyrukynd |
| Kiniksa Pharmaceuticals International, Plc | $16.76 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $16.42 | 2023 | |
| Radius Health, INC. | $15.45 | 2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $15.39 | 2024 | Strensiq |
| Janssen Pharmaceuticals, INC | $13.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Duvvuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.